Literature DB >> 10882732

The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2.

R Battistutta1, S Sarno, E De Moliner, E Papinutto, G Zanotti, L A Pinna.   

Abstract

The structure of a complex between the catalytic subunit of Zea mays CK2 and the nucleotide binding site-directed inhibitor emodin (3-methyl-1,6,8-trihydroxyanthraquinone) was solved at 2.6-A resolution. Emodin enters the nucleotide binding site of the enzyme, filling a hydrophobic pocket between the N-terminal and the C-terminal lobes, in the proximity of the site occupied by the base rings of the natural co-substrates. The interactions between the inhibitor and CK2 alpha are mainly hydrophobic. Although the C-terminal domain of the enzyme is essentially identical to the ATP-bound form, the beta-sheet in the N-terminal domain is altered by the presence of emodin. The structural data presented here highlight the flexibility of the kinase domain structure and provide information for the design of selective ATP competitive inhibitors of protein kinase CK2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882732     DOI: 10.1074/jbc.M004257200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Structural basis for dual nucleotide selectivity of aminoglycoside 2''-phosphotransferase IVa provides insight on determinants of nucleotide specificity of aminoglycoside kinases.

Authors:  Kun Shi; Albert M Berghuis
Journal:  J Biol Chem       Date:  2012-02-24       Impact factor: 5.157

Review 2.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

3.  Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).

Authors:  Tatyana Adayev; Jerzy Wegiel; Yu-Wen Hwang
Journal:  Arch Biochem Biophys       Date:  2010-12-24       Impact factor: 4.013

4.  Development and exploitation of CK2 inhibitors.

Authors:  Stefania Sarno; Maria Ruzzene; Pietrogiulio Frascella; Mario A Pagano; Flavio Meggio; Alfonso Zambon; Marco Mazzorana; Giovanni Di Maira; Vittorio Lucchini; Lorenzo A Pinna
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

Review 5.  Structural and functional determinants of protein kinase CK2α: facts and open questions.

Authors:  Roberto Battistutta; Graziano Lolli
Journal:  Mol Cell Biochem       Date:  2011-07-08       Impact factor: 3.396

6.  Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90β as a Novel Mechanism of Rifampin-induced MDR1 Expression.

Authors:  So Won Kim; Md Hasanuzzaman; Munju Cho; Ye Rang Heo; Min-Jung Ryu; Na-Young Ha; Hyun June Park; Hyung-Yeon Park; Jae-Gook Shin
Journal:  J Biol Chem       Date:  2015-05-20       Impact factor: 5.157

7.  Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome.

Authors:  Stefan Uhle; Ohad Medalia; Richard Waldron; Renate Dumdey; Peter Henklein; Dawadschargal Bech-Otschir; Xiaohua Huang; Matthias Berse; Joseph Sperling; Rüdiger Schade; Wolfgang Dubiel
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

8.  Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole.

Authors:  R Battistutta; E De Moliner; S Sarno; G Zanotti; L A Pinna
Journal:  Protein Sci       Date:  2001-11       Impact factor: 6.725

Review 9.  A structural insight into CK2 inhibition.

Authors:  Marco Mazzorana; Lorenzo A Pinna; Roberto Battistutta
Journal:  Mol Cell Biochem       Date:  2008-07-15       Impact factor: 3.396

10.  Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition.

Authors:  David Komander; Gursant S Kular; Jennifer Bain; Matthew Elliott; Dario R Alessi; Daan M F Van Aalten
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.